In a challenging market environment, Adc Therapeutics SA (ADCT) stock has reached a 52-week low, trading at $1.42, with a market capitalization of $138 million. According to InvestingPro analysis, the ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

In a report released on January 21, Kelly Shi from Jefferies maintained a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $10.00. The company’s shares closed ...

LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer ...

LAUSANNE, Switzerland, Feb. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced ...

LAUSANNE, Switzerland - ADC Therapeutics SA (NYSE: ADCT) reported a narrower-than-expected loss for the first quarter of 2024, sending shares soaring 26.3% as the market responded ...